<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474264</url>
  </required_header>
  <id_info>
    <org_study_id>0594-14-RMC</org_study_id>
    <nct_id>NCT02474264</nct_id>
  </id_info>
  <brief_title>The Link Between BRCA Mutation and Endothelial Function</brief_title>
  <official_title>The Link Between BRCA Mutation and Endothelial Function - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of BRCA1&amp;2 mutations on cardiovascular diseases by to
      comparing the endothelial function of male BRCA mutation carriers with that of age matched
      non-BRCA mutation carriers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reactive hyperemia index will be assessed using the Endo-PAT2000</measure>
    <time_frame>at baseline</time_frame>
    <description>will be assessed using the Endo-PAT2000</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The level of high sensitivity troponin (hsTn) - a cardiovascular risk biomarker will be measured</measure>
    <time_frame>at baseline</time_frame>
    <description>high sensitivity troponin (hsTn)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of C-reactive protein - a cardiovascular risk biomarker will be measured</measure>
    <time_frame>at baseline</time_frame>
    <description>C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of D-dimer - a cardiovascular risk biomarker will be measured</measure>
    <time_frame>at baseline</time_frame>
    <description>D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of N-terminal pro-brain natriuretic peptide (NT-proBNP) - a cardiovascular risk biomarker will be measured</measure>
    <time_frame>at baseline</time_frame>
    <description>N-terminal pro-brain natriuretic peptide (NT-proBNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Progenitor Cells profile (EPC) - will be characterized to evaluate endothelial injury.</measure>
    <time_frame>at baseline</time_frame>
    <description>Endothelial Progenitor Cells (EPC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Endothelial Cells profile (CEC) - will be characterized to evaluate endothelial injury.</measure>
    <time_frame>at baseline</time_frame>
    <description>Circulating Endothelial Cells (CEC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>BRCA1 Gene Mutation</condition>
  <condition>BRCA2 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>male BRCA mutations carriers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Endothelial function assessment and Cardiovascular biomarkers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy males - control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Endothelial function assessment and Cardiovascular biomarkers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endothelial function assessment</intervention_name>
    <description>reactive hyperemia index</description>
    <arm_group_label>male BRCA mutations carriers</arm_group_label>
    <arm_group_label>healthy males - control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiovascular biomarkers</intervention_name>
    <description>Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)</description>
    <arm_group_label>male BRCA mutations carriers</arm_group_label>
    <arm_group_label>healthy males - control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endothelial cells</intervention_name>
    <description>Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.</description>
    <arm_group_label>male BRCA mutations carriers</arm_group_label>
    <arm_group_label>healthy males - control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known carrier or non-carrier, confirmed by genetic testing of BRCA 1/2 mutation

          -  Able and willing to sign an informed consent

        Exclusion Criteria:

          -  History of, or current, malignancy

          -  History of:

               -  Myocardial infarction

               -  Ischemic or Hemorrhagic cerebrovascular conditions

               -  Arterial embolic and thrombotic events

               -  Ischemic heart disease

               -  Prior coronary artery or ilio-femoral artery revascularization (percutaneous or
                  surgical procedures)

               -  Peripheral vascular disease (e.g. claudication, prior vascular
                  surgery/intervention)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Margel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabn Medical Center, Beilinson Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Margel, MD, PhD</last_name>
    <phone>+972(0)39376553</phone>
    <email>sdmargel@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Margel, MD PhD</last_name>
      <phone>+972(0)39376553</phone>
    </contact>
    <investigator>
      <last_name>David Margel, MD Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2015</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

